Strunk T, Härtel C, Schultz C
Campus Lubeck, Department of Paediatrics, Ratzeburger Allee 160, 23538 Lubeck, Germany.
Arch Dis Child Fetal Neonatal Ed. 2004 Jul;89(4):F364-6. doi: 10.1136/adc.2003.041533.
There is a high incidence of hypoxic-ischaemic brain injury and intraventricular haemorrhage in newborn infants, particularly those born preterm. Many die during the newborn period or suffer permanent neurodevelopmental handicaps. Hypoxic brain injury develops over several hours and could potentially be influenced by intervention. At present, no drug exists that effectively prevents infant brain injury or ameliorates detrimental neurodevelopmental effects. The hypothesis is put forward that systemic administration of recombinant human erythropoietin positively affects the neurodevelopmental outcome of high risk preterm infants affected by brain injury. A multicentre, randomised, placebo controlled study is proposed to prospectively test this hypothesis.
新生儿，尤其是早产儿，发生缺氧缺血性脑损伤和脑室内出血的几率很高。许多婴儿在新生儿期死亡或患有永久性神经发育障碍。缺氧性脑损伤在数小时内发展，可能会受到干预的影响。目前，尚无有效预防婴儿脑损伤或改善有害神经发育影响的药物。有人提出假设，即全身给予重组人促红细胞生成素会对受脑损伤影响的高危早产儿的神经发育结局产生积极影响。拟进行一项多中心、随机、安慰剂对照研究，以前瞻性地验证这一假设。
